Scarica l'app Stockscreener
101.11
3.83%
3.73
Dopo l'orario di chiusura:
101.03
-0.08
-0.08%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ILMN Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$97.38
Aprire:
$98.2
Volume 24 ore:
1.62M
Relative Volume:
0.71
Capitalizzazione di mercato:
$15.54B
Reddito:
$4.34B
Utile/perdita netta:
$-965.00M
Rapporto P/E:
-16.66
EPS:
-6.07
Flusso di cassa netto:
$869.00M
1 W Prestazione:
+7.07%
1M Prestazione:
+1.87%
6M Prestazione:
-0.66%
1 anno Prestazione:
-15.54%
Intervallo 1D:
$98.02
$101.37
Intervallo di 1 settimana:
$93.32
$101.37
Portata 52W:
$68.70
$156.66
Illumina Inc Stock (ILMN) Company Profile
Nome
Illumina Inc
Settore
Industria
Telefono
(858) 202-4500
Indirizzo
5200 ILLUMINA WAY, SAN DIEGO, CA
Confronta ILMN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ILMN
Illumina Inc
|
101.11 | 15.00B | 4.34B | -965.00M | 869.00M | -6.07 |
|
TMO
Thermo Fisher Scientific Inc
|
484.79 | 174.60B | 43.21B | 6.58B | 6.17B | 17.29 |
|
DHR
Danaher Corp
|
209.14 | 143.04B | 24.01B | 3.41B | 4.86B | 4.70 |
|
IDXX
Idexx Laboratories Inc
|
664.16 | 52.17B | 4.04B | 985.66M | 774.34M | 12.01 |
|
A
Agilent Technologies Inc
|
120.29 | 32.42B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
190.23 | 30.62B | 15.50B | 1.33B | 2.16B | 7.34 |
Illumina Inc Stock (ILMN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-11 | Downgrade | Scotiabank | Sector Outperform → Sector Perform |
| 2025-03-04 | Reiterato | Citigroup | Neutral |
| 2025-02-28 | Downgrade | HSBC Securities | Buy → Hold |
| 2025-02-10 | Downgrade | Barclays | Equal Weight → Underweight |
| 2025-02-07 | Downgrade | TD Cowen | Buy → Hold |
| 2024-12-11 | Downgrade | Citigroup | Buy → Neutral |
| 2024-11-12 | Ripresa | Morgan Stanley | Equal-Weight |
| 2024-10-17 | Aggiornamento | HSBC Securities | Hold → Buy |
| 2024-08-28 | Aggiornamento | Argus | Hold → Buy |
| 2024-08-16 | Aggiornamento | Daiwa Securities | Neutral → Buy |
| 2024-08-14 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2024-08-14 | Aggiornamento | TD Cowen | Hold → Buy |
| 2024-07-10 | Aggiornamento | Citigroup | Neutral → Buy |
| 2024-06-03 | Ripresa | Jefferies | Hold |
| 2024-01-16 | Downgrade | HSBC Securities | Buy → Hold |
| 2024-01-04 | Downgrade | TD Cowen | Outperform → Market Perform |
| 2023-12-18 | Aggiornamento | Scotiabank | Sector Perform → Sector Outperform |
| 2023-12-15 | Aggiornamento | Bernstein | Underperform → Mkt Perform |
| 2023-12-14 | Iniziato | Guggenheim | Buy |
| 2023-12-14 | Iniziato | Stephens | Overweight |
| 2023-12-13 | Iniziato | Wolfe Research | Outperform |
| 2023-12-12 | Downgrade | BofA Securities | Neutral → Underperform |
| 2023-12-11 | Aggiornamento | Citigroup | Sell → Neutral |
| 2023-11-10 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2023-09-28 | Iniziato | Bernstein | Underperform |
| 2023-07-05 | Ripresa | JP Morgan | Neutral |
| 2023-01-25 | Downgrade | Argus | Buy → Hold |
| 2023-01-05 | Iniziato | Scotiabank | Sector Perform |
| 2022-12-12 | Downgrade | Citigroup | Neutral → Sell |
| 2022-12-07 | Iniziato | RBC Capital Mkts | Outperform |
| 2022-10-04 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2022-09-28 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2022-08-25 | Iniziato | Credit Suisse | Neutral |
| 2022-07-13 | Downgrade | Barclays | Equal Weight → Underweight |
| 2022-01-18 | Aggiornamento | Stifel | Hold → Buy |
| 2022-01-11 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2022-01-07 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2022-01-06 | Ripresa | Morgan Stanley | Equal-Weight |
| 2022-01-06 | Ripresa | Piper Sandler | Overweight |
| 2021-10-15 | Ripresa | Cowen | Outperform |
| 2021-08-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2021-06-01 | Aggiornamento | Evercore ISI | Underperform → In-line |
| 2021-03-31 | Downgrade | Atlantic Equities | Overweight → Neutral |
| 2021-03-31 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2021-03-03 | Iniziato | Barclays | Underweight |
| 2020-12-22 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2020-12-17 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2020-10-13 | Downgrade | Guggenheim | Buy → Neutral |
| 2020-09-30 | Iniziato | Atlantic Equities | Overweight |
| 2020-09-29 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2020-09-22 | Downgrade | Stifel | Buy → Hold |
| 2020-09-22 | Downgrade | UBS | Buy → Neutral |
| 2020-09-21 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-09-21 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-09-09 | Iniziato | Morgan Stanley | Equal-Weight |
| 2020-08-07 | Downgrade | Evercore ISI | In-line → Underperform |
| 2020-08-07 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2020-07-07 | Downgrade | Guggenheim | Buy → Neutral |
| 2020-04-24 | Downgrade | Citigroup | Buy → Neutral |
| 2020-04-21 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2020-01-08 | Iniziato | Wells Fargo | Underweight |
| 2020-01-07 | Iniziato | Citigroup | Buy |
| 2020-01-02 | Downgrade | Evercore ISI | Outperform → In-line |
| 2019-11-15 | Iniziato | Stifel | Buy |
| 2019-10-25 | Iniziato | Guggenheim | Buy |
Mostra tutto
Illumina Inc Borsa (ILMN) Ultime notizie
Now that NGS is more affordable, how can we make it easier? - Illumina
Illumina’s Q2 Earnings Call: Our Top 5 Analyst Questions - Yahoo Finance
[Latest] US Personalized Medicine Market Size/Share Worth USD 252.93 Billion by 2034 at a 17.32% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis) - GlobeNewswire Inc.
Centene, RadNet, Evolent Health, Illumina, and Charles River Laboratories Shares Are Soaring, What You Need To Know - Yahoo Finance
Illumina Sees Future Rebound in China Sales - San Diego Business Journal
Daiwa Securities Downgrades Illumina to Neutral From Outperform, Adjusts Price Target to $94 From $124 - MarketScreener
US Personalized Medicine Market Trends and Company Analysis - GlobeNewswire
US Personalized Medicine Market Trends and Company Analysis Report 2025-2033 Featuring Abbott, GE, Aadi Bioscience, Illumina, QIAGEN, Eli Lilly and Co, Takeda, AbbVie, F. Hoffmann-La Roche - Yahoo Finance
How Illumina Inc. stock performs during market volatilityMaximum Yield Stock Screener - classian.co.kr
Standard BioTools Announces SomaLogic Sale to Illumina - TipRanks
Latest Cybersecurity False Claims Act Settlement with Diagnostics Provider Focuses on Sensitive Health Systems - Inside Privacy
Illumina price leans on SMA supportForecast today11-08-2025 - Economies.com
DNA Microarray Market to Grow at 9% CAGR, Driven by Personalized - openPR.com
Single Cell Genome Sequencing Market is evolving rapidly Through 2025 To 2032 | Illumina, Inc., Fludigim Corporation - openPR.com
Is Illumina Inc. a strong growth stockEarnings Surprise Driven Picks - thegnnews.com
What makes Illumina Inc. stock price move sharplyMulti-Sector Diversified Watchlist - thegnnews.com
What are analysts’ price targets for Illumina Inc.Weekly Oversold Bounce Candidates - thegnnews.com
DOJ Settlement With Medical Technology Company Signals Expanding Cybersecurity FCA Risk for Life Sciences Companies - JD Supra
Illumina (NASDAQ:ILMN) Strong Profits May Be Masking Some Underlying Issues - simplywall.st
DOJ Secures First of Its Kind Cybersecurity False Claims Act Settlement - JD Supra
Bioinformatics Market Booms with Rapid Growth Expected by 2032 | Active Motif, Inc., Illumina - openPR.com
Illumina Reaches $9.8M Deal in Cybersecurity False Claims Probe - Homeland Security Today
Illumina Stock Slides 0.69 as Mixed Analyst Reactions Highlight 490th-Ranked Volume Amid Profitability Surge and Growth Doubts - AInvest
Illumina pays $9.8 million to settle DOJ claims over cybersecurity failures in government contracts - teiss
“False” Sense of Security: DOJ Announces False Claims Act Settlements Related to Failure to Comply with Cybersecurity Requirements - JD Supra
Does Illumina (ILMN) have an Attractive Risk-Reward Opportunity for Long-Term Investors? - MSN
Illumina Inc. to Pay $9.8M to Resolve False Claims Act Allegations Arising from Cybersecurity Vulnerabilities in Genomic Sequencing Systems - Sierra Sun Times
Illumina (ILMN) Reliance on International Sales: What Investors Need to Know - Yahoo Finance
Illumina, Inc. Just Recorded A 76% EPS Beat: Here's What Analysts Are Forecasting Next - simplywall.st
DOJ reaches USD 9.8M settlement with Illumina - Medical Buyer
Genomic Systems Maker Settles Cybersecurity Lawsuit - Manufacturing Business Technology
DOJ reaches $9.8M settlement with Illumina over cyber whistleblower claims - MedTech Dive
Unexpected Trends Reshaping the U.S. Genomics Market by 2032 - openPR.com
Insider Buying Surges at BEEX Holdings: Chubb and Illumina Lead the Way - AInvest
How the U.S. Precision Medicine Market Will Evolve by 2032 - openPR.com
Illumina’s SomaLogic acquisition may face GRAIL-like regulatory hurdles - ION Analytics
Is Illumina, Inc. (NASDAQ:ILMN) Potentially Undervalued? - au.finance.yahoo.com
Multi-Omics Market to Surpass US$33.25 Billion by 2033, Driven - openPR.com
Illumina Second Quarter 2025 Earnings: EPS Beats Expectations - Yahoo Finance
Illumina: The Stock Is Still Undervalued (NASDAQ:ILMN) - Seeking Alpha
Illumina Settles Allegations of Cyber Vulnerabilities in Genomic Sequencing for $9.8M - Claims Journal
What catalysts could drive Illumina Inc. stock higher in 2025Capitalize on market trends with confidence - Jammu Links News
What is Illumina Inc. company’s growth strategyGame-changing returns - jammulinksnews.com
What are Illumina Inc. company’s key revenue driversSuperior stock growth - Jammu Links News
Should I hold or sell Illumina Inc. stock in 2025Extraordinary market timing - Jammu Links News
Illumina, Inc.'s (NASDAQ:ILMN) Stock Is Going Strong: Have Financials A Role To Play? - simplywall.st
How does Illumina Inc. compare to its industry peersBuild a balanced portfolio for long-term success - Jammu Links News
Published on: 2025-08-03 17:43:00 - Jammu Links News
What is the dividend policy of Illumina Inc. stockBreakthrough profits - Jammu Links News
Illumina Inc. Stock Analysis and ForecastDiscover stock picks with superior returns - Jammu Links News
How strong is Illumina Inc. company’s balance sheetInvest confidently with professional guidance - Jammu Links News
Illumina Inc Azioni (ILMN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.96%
1.32%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):